

**Testimony in Opposition to LD 1847 – An Act to Institute Testing and Tracking of Medical Use Cannabis and Cannabis Products Similar to Adult Use Cannabis and Cannabis Products**

Dear Members of the Veterans and Legal Affairs Committee,

My name is Andrew Barbash, and I am a Massachusetts medical marijuana patient who relies on Maine's medical cannabis program monthly to access high-quality medications from trusted caregivers at reasonable prices.

LD 1847, while aiming to align medical cannabis regulations with those of adult-use cannabis, could inadvertently impose burdensome testing and tracking requirements on small-scale caregivers. These additional mandates may increase operational costs, potentially leading to higher prices and reduced accessibility for patients like myself who depend on affordable, quality medical cannabis.

Maine's caregiver model has been instrumental in providing personalized care and maintaining the affordability of medical cannabis. Implementing stringent testing and tracking protocols similar to the adult-use market could disrupt this model, limiting patient access and choice.

I respectfully urge you to consider the potential unintended consequences of LD 1847 on patient access and caregiver sustainability. Maintaining a balance between safety and accessibility is crucial for the well-being of medical cannabis patients.

Thank you for your attention to this matter.

Sincerely,  
Andrew Barbash  
5086674761  
[andrew@absnacks.com](mailto:andrew@absnacks.com)  
18 Rockwell Dr  
Shrewsbury, MA 01545

Andrew Barbash  
Shrewsbury, MA  
LD 1847

Testimony in Opposition to LD 1847 – An Act to Institute Testing and Tracking of Medical Use Cannabis and Cannabis Products Similar to Adult Use Cannabis and Cannabis Products

Dear Members of the Veterans and Legal Affairs Committee,

My name is Andrew Barbash, and I am a Massachusetts medical marijuana patient who relies on Maine's medical cannabis program monthly to access high-quality medications from trusted caregivers at reasonable prices.

LD 1847, while aiming to align medical cannabis regulations with those of adult-use cannabis, could inadvertently impose burdensome testing and tracking requirements on small-scale caregivers. These additional mandates may increase operational costs, potentially leading to higher prices and reduced accessibility for patients like myself who depend on affordable, quality medical cannabis.

Maine's caregiver model has been instrumental in providing personalized care and maintaining the affordability of medical cannabis. Implementing stringent testing and tracking protocols similar to the adult-use market could disrupt this model, limiting patient access and choice.

I respectfully urge you to consider the potential unintended consequences of LD 1847 on patient access and caregiver sustainability. Maintaining a balance between safety and accessibility is crucial for the well-being of medical cannabis patients.

Thank you for your attention to this matter.

Sincerely,

Andrew Barbash  
5086674761  
andrew@absnacks.com  
18 Rockwell Dr  
Shrewsbury, MA 01545